探讨患者偏好在肝细胞癌治疗决策中的作用:一项定性研究。

IF 1.7 Q3 HEALTH CARE SCIENCES & SERVICES
MDM Policy and Practice Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI:10.1177/23814683251340055
Andrew M Moon, Daniel Richardson, Gabriel V Lupu, Donna M Evon, Hanna K Sanoff, Jessica Carda-Auten, Randall Teal, Myra Waheed, Ethan Basch, David M Mauro, Ted K Yanagihara, David A Gerber, Neil D Shah, Oren K Fix, Hersh Shroff, Tammy Triglianos, Jonathan D Sorah, Jingquan Jia, Ashwin Somasundaram, Lynne I Wagner, Michael D Kappelman, Matthew Schooler, Julia R Phillips, Hiwot A Ekuban, Ariel E Sanderford, A Sidney Barritt
{"title":"探讨患者偏好在肝细胞癌治疗决策中的作用:一项定性研究。","authors":"Andrew M Moon, Daniel Richardson, Gabriel V Lupu, Donna M Evon, Hanna K Sanoff, Jessica Carda-Auten, Randall Teal, Myra Waheed, Ethan Basch, David M Mauro, Ted K Yanagihara, David A Gerber, Neil D Shah, Oren K Fix, Hersh Shroff, Tammy Triglianos, Jonathan D Sorah, Jingquan Jia, Ashwin Somasundaram, Lynne I Wagner, Michael D Kappelman, Matthew Schooler, Julia R Phillips, Hiwot A Ekuban, Ariel E Sanderford, A Sidney Barritt","doi":"10.1177/23814683251340055","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background.</b> Hepatocellular carcinoma (HCC) treatment decisions are becoming increasingly complex as new treatment options emerge. Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient-provider discussions, improve treatment development, and inform HCC treatment guidelines. We performed a qualitative study involving patients with HCC and medical providers to assess the role of patient preferences in HCC treatment choices. <b>Methods.</b> Patient participants included those with HCC seen within a single tertiary care center. Provider participants involved physicians and advanced practice providers who cared for patients with HCC from a single center. Baseline and posttreatment patient interviews were conducted by trained qualitative research experts, informed by semi-structured interview guides, and analyzed using thematic analysis with pilot-tested codebooks. Summaries included a narrative description of the themes and subthemes that emerged related to each code, and illustrative quotes were used to highlight each theme. <b>Results.</b> The baseline interview involved 30 patients with HCC (22 of whom participated in follow-up interviews) and 10 providers who cared for patients with HCC. Patients identified factors considered when making treatment decisions included provider confidence and experience, patient prior cancer experiences, other health issues, and faith. Providers primarily discussed the role of Barcelona Clinic Liver Cancer stage, liver function, performance status, and eligibility of liver transplantation in making treatment recommendations. There was general agreement among providers that there is a need to better understand the role of patient values to improve care for HCC. <b>Limitations.</b> Qualitative interviews were limited to patients and providers from a single center. <b>Conclusions.</b> This qualitative study provided information on the variety of values considered by both patients and providers in HCC treatment decisions and the importance of considering tradeoffs of efficacy, toxicity, and inconvenience/costs.</p><p><strong>Highlights: </strong>Hepatocellular carcinoma (HCC) treatment decisions are often complex and may become increasingly so as new treatment options emerge.Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient-provider discussions, facilitate patient-centered trials to develop new treatments, and inform HCC treatment guidelines.This qualitative study of patients and providers provided information on the values considered in HCC treatment decisions and the importance of considering the tradeoffs of efficacy, toxicity, and inconvenience/costs.These insights can be used to develop preference elicitation tools, perform large-scale preference elicitation surveys, and systematically assess and incorporate patient preferences into treatment decisions.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"10 1","pages":"23814683251340055"},"PeriodicalIF":1.7000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123149/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study.\",\"authors\":\"Andrew M Moon, Daniel Richardson, Gabriel V Lupu, Donna M Evon, Hanna K Sanoff, Jessica Carda-Auten, Randall Teal, Myra Waheed, Ethan Basch, David M Mauro, Ted K Yanagihara, David A Gerber, Neil D Shah, Oren K Fix, Hersh Shroff, Tammy Triglianos, Jonathan D Sorah, Jingquan Jia, Ashwin Somasundaram, Lynne I Wagner, Michael D Kappelman, Matthew Schooler, Julia R Phillips, Hiwot A Ekuban, Ariel E Sanderford, A Sidney Barritt\",\"doi\":\"10.1177/23814683251340055\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background.</b> Hepatocellular carcinoma (HCC) treatment decisions are becoming increasingly complex as new treatment options emerge. Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient-provider discussions, improve treatment development, and inform HCC treatment guidelines. We performed a qualitative study involving patients with HCC and medical providers to assess the role of patient preferences in HCC treatment choices. <b>Methods.</b> Patient participants included those with HCC seen within a single tertiary care center. Provider participants involved physicians and advanced practice providers who cared for patients with HCC from a single center. Baseline and posttreatment patient interviews were conducted by trained qualitative research experts, informed by semi-structured interview guides, and analyzed using thematic analysis with pilot-tested codebooks. Summaries included a narrative description of the themes and subthemes that emerged related to each code, and illustrative quotes were used to highlight each theme. <b>Results.</b> The baseline interview involved 30 patients with HCC (22 of whom participated in follow-up interviews) and 10 providers who cared for patients with HCC. Patients identified factors considered when making treatment decisions included provider confidence and experience, patient prior cancer experiences, other health issues, and faith. Providers primarily discussed the role of Barcelona Clinic Liver Cancer stage, liver function, performance status, and eligibility of liver transplantation in making treatment recommendations. There was general agreement among providers that there is a need to better understand the role of patient values to improve care for HCC. <b>Limitations.</b> Qualitative interviews were limited to patients and providers from a single center. <b>Conclusions.</b> This qualitative study provided information on the variety of values considered by both patients and providers in HCC treatment decisions and the importance of considering tradeoffs of efficacy, toxicity, and inconvenience/costs.</p><p><strong>Highlights: </strong>Hepatocellular carcinoma (HCC) treatment decisions are often complex and may become increasingly so as new treatment options emerge.Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient-provider discussions, facilitate patient-centered trials to develop new treatments, and inform HCC treatment guidelines.This qualitative study of patients and providers provided information on the values considered in HCC treatment decisions and the importance of considering the tradeoffs of efficacy, toxicity, and inconvenience/costs.These insights can be used to develop preference elicitation tools, perform large-scale preference elicitation surveys, and systematically assess and incorporate patient preferences into treatment decisions.</p>\",\"PeriodicalId\":36567,\"journal\":{\"name\":\"MDM Policy and Practice\",\"volume\":\"10 1\",\"pages\":\"23814683251340055\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123149/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MDM Policy and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/23814683251340055\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MDM Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23814683251340055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

背景。随着新的治疗方案的出现,肝细胞癌(HCC)的治疗决策变得越来越复杂。更好地了解治疗决策中的权衡和患者偏好将加强患者与提供者的讨论,改善治疗发展,并为HCC治疗指南提供信息。我们进行了一项涉及HCC患者和医疗提供者的定性研究,以评估患者偏好在HCC治疗选择中的作用。方法。患者参与者包括在单一三级医疗中心就诊的HCC患者。提供者参与者包括来自单一中心的照顾HCC患者的医生和高级实践提供者。基线和治疗后患者访谈由训练有素的定性研究专家进行,由半结构化访谈指南提供信息,并使用专题分析和试点测试的代码本进行分析。摘要包括与每个代码相关的主题和子主题的叙述性描述,并使用说明性引用来突出每个主题。结果。基线访谈涉及30名HCC患者(其中22人参加了随访访谈)和10名治疗HCC患者的医护人员。患者确定在做出治疗决定时考虑的因素包括医生的信心和经验、患者以前的癌症经历、其他健康问题和信仰。提供者主要讨论了巴塞罗那诊所肝癌分期、肝功能、表现状态和肝移植资格在制定治疗建议中的作用。提供者普遍认为有必要更好地了解患者价值在改善HCC治疗中的作用。的局限性。定性访谈仅限于来自单一中心的患者和提供者。结论。本定性研究提供了患者和提供者在HCC治疗决策中考虑的各种价值的信息,以及考虑疗效、毒性和不便/成本权衡的重要性。重点:肝细胞癌(HCC)的治疗决策通常是复杂的,随着新的治疗方案的出现,可能会变得越来越复杂。更好地了解治疗决策中的权衡和患者偏好将加强患者与提供者的讨论,促进以患者为中心的试验以开发新的治疗方法,并为HCC治疗指南提供信息。这项对患者和提供者的定性研究提供了HCC治疗决策所考虑的价值以及考虑疗效、毒性和不便/成本权衡的重要性。这些见解可用于开发偏好激发工具,进行大规模偏好激发调查,并系统地评估并将患者偏好纳入治疗决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study.

Background. Hepatocellular carcinoma (HCC) treatment decisions are becoming increasingly complex as new treatment options emerge. Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient-provider discussions, improve treatment development, and inform HCC treatment guidelines. We performed a qualitative study involving patients with HCC and medical providers to assess the role of patient preferences in HCC treatment choices. Methods. Patient participants included those with HCC seen within a single tertiary care center. Provider participants involved physicians and advanced practice providers who cared for patients with HCC from a single center. Baseline and posttreatment patient interviews were conducted by trained qualitative research experts, informed by semi-structured interview guides, and analyzed using thematic analysis with pilot-tested codebooks. Summaries included a narrative description of the themes and subthemes that emerged related to each code, and illustrative quotes were used to highlight each theme. Results. The baseline interview involved 30 patients with HCC (22 of whom participated in follow-up interviews) and 10 providers who cared for patients with HCC. Patients identified factors considered when making treatment decisions included provider confidence and experience, patient prior cancer experiences, other health issues, and faith. Providers primarily discussed the role of Barcelona Clinic Liver Cancer stage, liver function, performance status, and eligibility of liver transplantation in making treatment recommendations. There was general agreement among providers that there is a need to better understand the role of patient values to improve care for HCC. Limitations. Qualitative interviews were limited to patients and providers from a single center. Conclusions. This qualitative study provided information on the variety of values considered by both patients and providers in HCC treatment decisions and the importance of considering tradeoffs of efficacy, toxicity, and inconvenience/costs.

Highlights: Hepatocellular carcinoma (HCC) treatment decisions are often complex and may become increasingly so as new treatment options emerge.Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient-provider discussions, facilitate patient-centered trials to develop new treatments, and inform HCC treatment guidelines.This qualitative study of patients and providers provided information on the values considered in HCC treatment decisions and the importance of considering the tradeoffs of efficacy, toxicity, and inconvenience/costs.These insights can be used to develop preference elicitation tools, perform large-scale preference elicitation surveys, and systematically assess and incorporate patient preferences into treatment decisions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
MDM Policy and Practice
MDM Policy and Practice Medicine-Health Policy
CiteScore
2.50
自引率
0.00%
发文量
28
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信